Close Menu

NEW YORK­ – Biocept said Thursday that it entered into a securities purchase agreement on March 4 with several institutional investors for the issuance and sale of 16,000,000 shares of its common stock at a price of $.41 per share, for gross proceeds of approximately $6.6 million in a registered direct offering priced at the market.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports on how meeting cancellations and related costs are affecting scientific societies.

In a new ruling, Canada's Supreme Court upheld the country's genetic non-discrimination law, the Canadian Press reports.

COVID-19 vaccine developers aim to avoid a complication that has affected efforts to develop vaccines for other diseases, the Wall Street Journal reports.

In PLOS this week: analysis of insertions throughout Shigella genomes, antigen production in malaria parasites, and more.